Patents by Inventor Ana Belén GARCÍA DELGADO

Ana Belén GARCÍA DELGADO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACYLATED COMPOUNDS FOR THE TREATMENT OF OCULAR PATHOLOGIES
    Publication number: 20220079965
    Abstract: A therapeutic use of acylated piceid derivative compounds in ocular pathologies, in particular retinitis pigmentosa and in age-related macular degeneration, inter alia. A method of treating and/or preventing ocular pathologies, wherein the method includes administering to a patient in need of treatment a therapeutically effective amount of a compound of general formula (I) or any of its isomers, their pharmaceutically acceptable salts, esters, tautomers, polymorphs, or hydrates.
    Type: Application
    Filed: November 30, 2021
    Publication date: March 17, 2022
    Inventors: Juan Carlos MORALES SÁNCHEZ, Pablo PEÑALVER PUENTE, Francisco Javier DÍAZ CORRALES, María Lourdes VALDÉS SÁNCHEZ, Ana Belén GARCÍA DELGADO, Adoración MONTERO SÁNCHEZ
  • Acylated compounds for the treatment of ocular pathologies
    Patent number: 11213536
    Abstract: The present invention relates to the therapeutic use of acylated piceid derivative compounds in ocular pathologies, in particular retinitis pigmentosa and in age-related macular degeneration.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: January 4, 2022
    Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
    Inventors: Juan Carlos Morales Sánchez, Pablo Peñalver Puente, Francisco Javier Díaz Corrales, María Lourdes Valdés Sánchez, Ana Belén García Delgado, Adoración Montero Sánchez
  • ACYLATED COMPOUNDS FOR THE TREATMENT OF OCULAR PATHOLOGIES
    Publication number: 20190275068
    Abstract: The present invention relates to the therapeutic use of acylated piceid derivative compounds in ocular pathologies, in particular retinitis pigmentosa and in age-related macular degeneration.
    Type: Application
    Filed: November 17, 2017
    Publication date: September 12, 2019
    Inventors: Juan Carlos MORALES SÁNCHEZ, Pablo PEÑALVER PUENTE, Francisco Javier DÍAZ CORRALES, María Lourdes VALDÉS SÁNCHEZ, Ana Belén GARCÍA DELGADO, Adoración MONTERO SÁNCHEZ
  • Spiropiperidylrifamycins for the treatment of mycobacterial infections
    Patent number: 7521458
    Abstract: The compounds of formula (1), their pharmaceutically acceptable salts and their solvates, wherein R1 is a radical selected between hydrogen and alkyl; R2 is selected from hydroxyalkyl, phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; R3 is selected from phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; the substituents of the phenyl of R2 and R3 selected from halogen, (C1-C4)-alkyl and (C1-C4)-alkoxyl and R4 is selected from hydrogen, alkyl allyl and homoallyl, they are useful for the treatment of mycobacterial infections, in particular for the treatment of infections produced by Mycobacterium tuberculosis, Mycobacterium avium-intracellulare complex or Mycobacterium kansasii.
    Type: Grant
    Filed: July 4, 2005
    Date of Patent: April 21, 2009
    Assignee: Universidad de Oviedo
    Inventors: José Barluenga Mur, Fernando Aznar Gómez, Maria Paz Cabal Naves, Ana Belén Garcia Delgado, Carlos Valdés Gómez
  • Spiropiperidylrifamycins for the Treatment of Mycobacterial Infections
    Publication number: 20070225266
    Abstract: The compounds of formula (1), their pharmaceutically acceptable salts and their solvates, wherein R1 is a radical selected between hydrogen and alkyl; R2 is selected from hydroxyalkyl, phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; R3 is selected from phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; the substituents of the phenyl of R2 and R3 selected from halogen, (C1-C4)-alkyl and (C1-C4)-alkoxyl and R4 is selected from hydrogen, alkyl allyl and homoallyl, they are useful for the treatment of mycobacterial infections, in particular for the treatment of infections produced by Mycobacterium tuberculosis, Mycobacterium avium-intracellulare complex or Mycobacterium kansasii.
    Type: Application
    Filed: July 4, 2005
    Publication date: September 27, 2007
    Inventors: Jose Barluenga Mur, Fernando Aznar Gomez, Maria Paz Cabal Naves, Ana Belen Garcia Delgado, Carlos Valdes Gomez